Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today announced it has completed a Series F round of financing in the amount of .
“These funds will be used to support our operations as we begin ramping production capabilities for the commercial launch of our PacBio RS system”
The financing round includes a previously announced $50 million strategic investment by Gen-Probe Incorporated, a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services.
"These funds will be used to support our operations as we begin ramping production capabilities for the commercial launch of our PacBio RS system," commented Hugh Martin, Chairman and Chief Executive Officer of Pacific Biosciences. The PacBio RS is the company's first product, a third generation sequencing system based on its Single Molecule Real Time (SMRT™) platform.
Pacific Biosciences has raised approximately $370 million in capital to date to support the development of its SMRT technology and PacBio RS system.
Revolutionary AI device utilizes few-molecule reservoir computing for blood glucose prediction